close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sqz Biotechnologies Company (NY:SQZ)

N/A UNCHANGED
Last Price Updated: 5:00 PM EDT, Jul 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sqz Biotechnologies Company

< Previous 1 2 3 4 5 Next >
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 127 companies set new 52-week lows. 
Via Benzinga
News headline image
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
From SQZ Biotechnologies Company
Via Business Wire
News headline image
US Stocks Mixed After Wednesday's Rally ↗
U.S. stocks traded mixed this morning, with the Dow Jones falling around 180 points on Thursday. 
Via Benzinga
Expert Ratings for SQZ Biotechnologies ↗
 
Via Benzinga
Analyst Ratings for SQZ Biotechnologies ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 72 companies hit new 52-week lows. 
Via Benzinga
News headline image
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
From SQZ Biotechnologies
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022 ↗
 
Via Benzinga
News headline image
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
From SQZ Biotechnologies
Via Business Wire
News headline image
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Top Ships Inc. (NASDAQ: TOPS) shares jumped 74% to $5.24. Vapotherm, Inc. (NASDAQ: VAPO) gained 48.8% to $1.3250. 
Via Benzinga
News headline image
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022 ↗
 
Via Benzinga
News headline image
Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges ↗
 
Via Benzinga
News headline image
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy
From SQZ Biotechnologies Company
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies to Present at Upcoming Investor Conferences
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Announces Leadership Transition
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 92 companies set new 52-week lows. 
Via Benzinga
News headline image
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation
From SQZ Biotechnologies Company
Via Business Wire
News headline image
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Presents Celiac Disease Tolerizing Antigen Carrier Preclinical Data at 2022 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
From SQZ Biotechnologies Company
Via Business Wire
News headline image
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs
From SQZ Biotechnologies Company
Via Business Wire
News headline image
Looking Into SQZ Biotechnologies's Return On Capital Employed ↗
SQZ Biotechnologies (NYSE:SQZ) brought in sales totaling $2.87 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 77.96%, resulting in a loss of $21.04 million. 
Via Benzinga
News headline image
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
From SQZ Biotechnologies
Via Business Wire
News headline image
SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer
From SQZ Biotechnologies
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022 ↗
Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of... 
Via Benzinga
News headline image
SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
From SQZ Biotechnologies
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today